News and Treatment Updates

Abstract Venetoclax (VEN) combined with azacitidine (AZA) or low-dose cytarabine (LDAC) has significantly improved outcomes for older patients with acute myeloid leukemia (AML). However, severe cytopenia often leads to treatment interruptions. Previous literature has reported…

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics…

ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2-year analysis of this prospective randomized phase III…

Abstract Introduction Azacitidine-venetoclax (AZA-VEN) has become a standard treatment in older or chemotherapy-ineligible AML patients. While the registration trial showed a median overall survival (OS) of 14.7 months, most real-world studies have not reproduced this result…

Summary Reduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). It remains unclear whether venetoclax, an…

Abstract Purpose: To evaluate the efficacy and safety of the cluster of differentiation 47-targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) in the phase III ENHANCE…

To the editor U2 small nuclear RNA auxiliary factor 1 (U2AF1) is one of the most frequently mutated genes in myelodysplastic neoplasms (MDS) [1, 2]. U2AF1 mutations predominantly occur at two hotspots (S34, Q157) within two zinc finger domains and disrupt pre-mRNA splicing by…

Highlights •There are no differences in NRM in patients receiving prior CAR T versus no CAR T. •There are no differences in GVHD in patients receiving prior CAR T versus no CAR T. •HCT within 3 months of CAR T had less grades III to IV acute GVHD. ABSTRACT It remains unclear…

In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib, decitabine/cedazuridine, and venetoclax was highly active in patients with relapsed or refractory acute myeloid leukemia (AML)…

TO THE EDITOR: In older patients with acute myeloid leukemia (AML), cure by hematopoietic stem cell transplantation (HSCT) is often not achieved after standard intensive chemotherapy (IC) because of intercurrent infections or other sequelae of IC. Extended, that is, 10-day…